What is Generate Biomedicines, Inc. 's stock issuance proceeds?

Generate Biomedicines, Inc. (GENB) reported stock issuance proceeds of $3.22M in Q1 2026.

What does stock issuance proceeds mean?

Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

Generate Biomedicines, Inc. GENB Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Piper SandlerPIPR

$519K-65.1%

SSR MiningSSRM

$422K—

RepligenRGEN

$0-100%

NNN REITNNN

$699K+6.7%

CHE

ChemedCHE

$1.31M-94.2%

Herc HoldingsHRI

$2M—

Other financials

Income statement

See full

Revenue$7.2M-18.1%

Operating income-$64.1M-33.1%

Net income-$61.4M-47.4%

EPS (diluted)-$1.07+34.0%

Balance sheet

See full

Cash & equivalents$160.6M-27.2%

Total debt$65.6M—

Total equity$514.8M+209%

Total assets$625.7M—

Cash flow

See full

Operating cash flow-$80.4M-51.2%

CapEx$3.8M+403%

Free cash flow-$84.2M-56.1%

Valuation

See full

Market cap$1.86B—

Enterprise value$1.76B—

Returns & leverage

See full

Debt / equity0.1×—

Current ratio9.2×—

Where this comes from

Reported directly by Generate Biomedicines, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.

The official record: Generate Biomedicines, Inc. ’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Generate Biomedicines, Inc. 's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Generate Biomedicines, Inc. 's stock issuance proceeds?: Generate Biomedicines, Inc. (GENB) reported stock issuance proceeds of $3.22M in Q1 2026.
What does stock issuance proceeds mean?: Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.